NDAQ Nasdaq Inc.

Annual Changes to the Nasdaq Biotechnology Index

Annual Changes to the Nasdaq Biotechnology Index

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced the results of the annual reconstitution of the Nasdaq Biotechnology Index (Nasdaq: NBI), which will become effective prior to market open on Monday, December 21, 2020.

The Index is designed to track the performance of a set of securities listed on The Nasdaq Stock Market® (Nasdaq®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).

The following 100 securities will be added to the Index:

EXCHANGESYMBOLCOMPANY NAME
NasdaqABUSArbutus Biopharma Corporation
NasdaqADAPAdaptimmune Therapeutics plc
NasdaqAKUSAkouos, Inc.
NasdaqALTAltimmune, Inc.
NasdaqALVRAlloVir, Inc.
NasdaqALXOALX Oncology Holdings Inc.
NasdaqAMTIApplied Molecular Transport Inc.
NasdaqANNXAnnexon, Inc.
NasdaqAPLTApplied Therapeutics, Inc.
NasdaqAPREAprea Therapeutics, Inc.
NasdaqARCTArcturus Therapeutics Holdings Inc.
NasdaqARQTArcutis Biotherapeutics, Inc.
NasdaqAVDLAvadel Pharmaceuticals plc
NasdaqAZNAstraZeneca PLC
NasdaqBDTXBlack Diamond Therapeutics, Inc.
NasdaqBEAMBeam Therapeutics Inc.
NasdaqBNTXBioNTech SE
NasdaqCABACabaletta Bio, Inc.
NasdaqCALACalithera Biosciences, Inc.
NasdaqCDXSCodexis, Inc.
NasdaqCLVSClovis Oncology, Inc.
NasdaqCNCEConcert Pharmaceuticals, Inc.
NasdaqCNSTConstellation Pharmaceuticals, Inc.
NasdaqCRNXCrinetics Pharmaceuticals, Inc.
NasdaqCRTXCortexyme, Inc.
NasdaqFMTXForma Therapeutics Holdings, Inc.
NasdaqFPRXFive Prime Therapeutics, Inc.
NasdaqFREQFrequency Therapeutics, Inc.
NasdaqFULCFulcrum Therapeutics, Inc.
NasdaqFUSNFusion Pharmaceuticals Inc.
NasdaqGBIOGeneration Bio Co.
NasdaqGMDAGamida Cell Ltd.
NasdaqHARPHarpoon Therapeutics, Inc.
NasdaqIDYAIDEAYA Biosciences, Inc.
NasdaqIGMSIGM Biosciences, Inc.
NasdaqIMABI-MAB
NasdaqIMUXImmunic, Inc.
NasdaqIMVTImmunovant, Inc.
NasdaqINZYInozyme Pharma, Inc.
NasdaqISEEIVERIC bio, Inc.
NasdaqITOSiTeos Therapeutics, Inc.
NasdaqJNCEJounce Therapeutics, Inc.
NasdaqKALAKala Pharmaceuticals, Inc.
NasdaqKALVKalVista Pharmaceuticals, Inc.
NasdaqKDMNKadmon Holdings, Inc.
NasdaqKDNYChinook Therapeutics, Inc.
NasdaqKLDOKaleido Biosciences, Inc.
NasdaqKMDAKamada Ltd.
NasdaqKNSAKiniksa Pharmaceuticals, Ltd.
NasdaqKROSKeros Therapeutics, Inc.
NasdaqKRYSKrystal Biotech, Inc.
NasdaqKZRKezar Life Sciences, Inc.
NasdaqLEGNLegend Biotech Corporation
NasdaqLRMRLarimar Therapeutics, Inc.
NasdaqMDGLMadrigal Pharmaceuticals, Inc.
NasdaqMNOVMediciNova, Inc.
NasdaqMRNSMarinus Pharmaceuticals, Inc.
NasdaqMRSNMersana Therapeutics, Inc.
NasdaqNKNantKwest, Inc.
NasdaqNKTXNkarta, Inc.
NasdaqNLTXNeoleukin Therapeutics, Inc.
NasdaqNRIXNurix Therapeutics, Inc.
NasdaqNVAXNovavax, Inc.
NasdaqNXTCNextCure, Inc.
NasdaqOCULOcular Therapeutix, Inc.
NasdaqODTOdonate Therapeutics, Inc.
NasdaqORICOric Pharmaceuticals, Inc.
NasdaqOVIDOvid Therapeutics Inc.
NasdaqPAHCPhibro Animal Health Corporation
NasdaqPANDPandion Therapeutics Inc.
NasdaqPASGPassage Bio, Inc.
NasdaqPCVXVaxcyte, Inc.
NasdaqPLRXPliant Therapeutics, Inc.
NasdaqPRTKParatek Pharmaceuticals, Inc.
NasdaqPRVBProvention Bio, Inc.
NasdaqPSTXPoseida Therapeutics, Inc.
NasdaqRAPTRAPT Therapeutics, Inc.
NasdaqRDHLRedhill Biopharma Ltd.
NasdaqREPLReplimune Group, Inc.
NasdaqRLAYRelay Therapeutics, Inc.
NasdaqRLMDRelmada Therapeutics, Inc.
NasdaqRNAAvidity Biosciences, Inc.
NasdaqRPRXRoyalty Pharma plc
NasdaqRPTXRepare Therapeutics Inc.
NasdaqRVMDRevolution Medicines, Inc.
NasdaqSELBSelecta Biosciences, Inc.
NasdaqSMMTSummit Therapeutics Inc.
NasdaqSNDXSyndax Pharmaceuticals, Inc.
NasdaqSPROSpero Therapeutics, Inc.
NasdaqSTROSutro Biopharma, Inc.
NasdaqSURFSurface Oncology, Inc.
NasdaqSWTXSpringWorks Therapeutics, Inc.
NasdaqTCRRTCR2 Therapeutics Inc.
NasdaqVIEViela Bio, Inc.
NasdaqVIRVir Biotechnology, Inc.
NasdaqVSTMVerastem, Inc.
NasdaqVYNEVYNE Therapeutics Inc.
NasdaqXENEXenon Pharmaceuticals Inc.
NasdaqZIOPZIOPHARM Oncology Inc
NasdaqZNTLZentalis Pharmaceuticals, Inc.

As a result of the reconstitution, the following 16 securities will be removed from the Index:

EXCHANGESYMBOLCOMPANY NAME
NasdaqADMAADMA Biologics Inc
NasdaqAMRSAmyris, Inc.
NasdaqAXNXAxonics Modulation Technologies, Inc.
NasdaqCERSCerus Corporation
NasdaqCRBPCorbus Pharmaceuticals Holdings, Inc.
NasdaqEOLSEvolus, Inc.
NasdaqEYPTEyePoint Pharmaceuticals, Inc.
NasdaqGLYCGlycoMimetics, Inc.
NasdaqGRTSGritstone Oncology, Inc.
NasdaqLXRXLexicon Pharmaceuticals, Inc.
NasdaqNVCRNovoCure Limited
NasdaqOPTNOptiNose, Inc.
NasdaqPRQRProQR Therapeutics N.V.
NasdaqQTRXQuanterix Corporation
NasdaqSLDBSolid Biosciences Inc.
NasdaqTECHBio-Techne Corp

About Nasdaq Global Indexes

Nasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, our index offering spans geographies and asset classes and includes diverse families such as the Dividend and Income (includes Dividend Achievers), Dorsey Wright, Fixed Income (includes BulletShares®), Global Equity, Green Economy, Nordic and Commodity indexes. We continuously offer new opportunities for financial product sponsors across a wide-spectrum of investable products and for asset managers to measure risk and performance. Nasdaq also provides exchange listing, custom index and design solutions to financial organizations worldwide.

About Nasdaq

Nasdaq (Nasdaq: NDAQ) is a global technology company serving the capital markets and other industries. Our diverse offering of data, analytics, software and services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions and career opportunities, visit us on , on Twitter , or at .

Media Relations Contact

Emily Pan

(646) 637-3964

Issuer & Investor Contact

Index Client Services

The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment strategy. Neither Nasdaq, Inc. nor any of its affiliates makes any recommendation to buy or sell any financial product or any representation about the financial condition of any company or fund. Statements regarding Nasdaq’s proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

- NDAQG-



EN
12/12/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nasdaq Inc.

 PRESS RELEASE

Nasdaq Announces End-of-Month Open Short Interest Positions in Nasdaq ...

Nasdaq Announces End-of-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date July 31, 2025 NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- At the end of the settlement date of July 31, 2025, short interest in 3,285 Nasdaq Global MarketSM securities totaled 13,683,072,188 shares compared with 13,792,841,090 shares in 3,260 Global Market issues reported for the prior settlement date of July 15, 2025. The mid-July short interest represents 2.15 days compared with 2.37 days for the prior reporting period. Short interest in 1,658 securities on The Nasdaq Capital MarketSM tot...

 PRESS RELEASE

Delisting of Securities from The Nasdaq Stock Market

Delisting of Securities from The Nasdaq Stock Market NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market announced today that it will delist the American depositary shares of Secoo Holding Limited. Secoo Holding Limited’s security was suspended on April 26, 2024 and has not traded on Nasdaq since that time. Nasdaq also announced today that it will delist the common stock of PaxMedica, Inc. PaxMedica, Inc.’s common stock was suspended on May 2, 2024 and has not traded on Nasdaq since that time. Nasdaq also announced today that it will delist ordinary shares of Etao Intern...

 PRESS RELEASE

Nasdaq Reports July 2025 Volumes

Nasdaq Reports July 2025 Volumes NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today reported monthly volumes for July 2025 on its Investor Relations website. A data sheet showing this information can be found at: About Nasdaq Nasdaq (Nasdaq: NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity ...

 PRESS RELEASE

Nasdaq Announces Mid-Month Open Short Interest Positions in Nasdaq Sto...

Nasdaq Announces Mid-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date July 15, 2025 NEW YORK, July 25, 2025 (GLOBE NEWSWIRE) -- At the end of the settlement date of July 15, 2025, short interest in 3,260 Nasdaq Global MarketSM securities totaled 13,792,841,090 shares compared with 14,138,758,851 shares in 3,257 Global Market issues reported for the prior settlement date of June 30, 2025. The mid-July short interest represents 2.37 days compared with 2.59 days for the prior reporting period. Short interest in 1,647 securities on The Nasdaq Capital MarketSM to...

 PRESS RELEASE

Nasdaq Announces Quarterly Dividend of $0.27 Per Share

Nasdaq Announces Quarterly Dividend of $0.27 Per Share NEW YORK, July 24, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Nasdaq, Inc. (Nasdaq: NDAQ) has declared a regular quarterly dividend of $0.27 per share on the company's outstanding common stock. The dividend is payable on September 26, 2025 to shareholders of record at the close of business on September 12, 2025. Future declarations of quarterly dividends and the establishment of future record and payment dates are subject to approval by the Board of Directors. About Nasdaq Nasdaq (Nasdaq: NDAQ) is a leading global technolog...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch